J I Schwartz

Summary

Publications

  1. ncbi Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet
    J I Schwartz
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Clin Pharmacol Ther 72:50-61. 2002
  2. ncbi Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers
    J I Schwartz
    Merck Research Laboratories, Rahway, New Jersey, USA
    J Clin Pharmacol 41:107-12. 2001
  3. ncbi Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients
    J I Schwartz
    Clinical Pharmacology Department, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Clin Pharmacol 41:1120-30. 2001
  4. ncbi In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics
    C Tang
    Drug Metabolism, Merck Research Laboratories, West Point, PA, USA
    Pharmacogenetics 11:223-35. 2001

Collaborators

Detail Information

Publications4

  1. ncbi Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet
    J I Schwartz
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Clin Pharmacol Ther 72:50-61. 2002
    ..This study compared directly the renal effects of two selective cyclooxygenase (COX)-2 inhibitors (rofecoxib and celecoxib) with naproxen (dual COX-1/COX-2 inhibitor) and placebo in healthy elderly subjects on a sodium-replete diet...
  2. ncbi Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers
    J I Schwartz
    Merck Research Laboratories, Rahway, New Jersey, USA
    J Clin Pharmacol 41:107-12. 2001
    ..Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin...
  3. ncbi Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients
    J I Schwartz
    Clinical Pharmacology Department, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Clin Pharmacol 41:1120-30. 2001
    ..It was concluded that rofecoxib at doses of 12.5, 25, and 50 mg once daily has no effect on the plasma concentrations or renal clearance (tested at the highest dose of rofecoxib) of methotrexate in rheumatoid arthritis patients...
  4. ncbi In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics
    C Tang
    Drug Metabolism, Merck Research Laboratories, West Point, PA, USA
    Pharmacogenetics 11:223-35. 2001
    ..2-fold (range, 1.6-3-fold) in two CYP2C9*1/*3 subjects and one CYP2C9*3/*3 subject receiving a single oral dose (200 mg) of the drug. In contrast, there was no significant change in celecoxib AUC in two subjects genotyped CYP2C9*1/*2...